BeOne Medicines (formerly BeiGene)
BeOne Medicines makes Brukinsa, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab.
Zanubrutinib, tislelizumab, sonrotoclax (BCL-2), BTK degrader BGB-16673.
Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.
Instead of blocking BTK, this pill destroys it, so it works even when the enzyme has mutated to escape every inhibitor.
Sonrotoclax is a more potent, shorter-acting successor to venetoclax. It was approved for mantle cell lymphoma in May 2026 and is in late-stage trials with zanubrutinib for CLL.
A Chinese-developed PD-1 blocker, engineered to avoid a side-channel that may blunt other PD-1 drugs, now approved in the US and EU for oesophageal and stomach cancer.
Zanubrutinib is the only BTK blocker to beat ibrutinib on both efficacy and safety in a head-to-head trial. It is now the most prescribed BTK inhibitor in CLL.
Pages like this
not linked directly; found by shared links- IdeaBTK degraders to pre-empt resistance in frontline CLL
Shares BGB-16673, Sonrotoclax, Chronic lymphocytic leukaemia, Acquired resistance to every therapy.
- TrialHERIZON-GEA-01
Shares Zanidatamab, Tislelizumab, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- ProductBendamustine
Shares Waldenström macroglobulinaemia, Mantle cell lymphoma, Follicular lymphoma, Chronic lymphocytic leukaemia.
- InstitutionCancer Hospital, Chinese Academy of Medical Sciences
Shares Jie Wang, National Medical Products Administration / Center for Drug Evaluation, Trials do not represent the people who get cancer, Regulatory divergence between regions.
- CollectionLymphoma Research Foundation (LRF)
Shares Waldenström macroglobulinaemia, Mantle cell lymphoma, Follicular lymphoma.
- TrialCaDAnCe-304
Shares BGB-16673, Chronic lymphocytic leukaemia, Acquired resistance to every therapy.
- TrialCELESTIAL-TNCLL
Shares Sonrotoclax, Zanubrutinib, Chronic lymphocytic leukaemia.
- IdeaMRD-guided treatment duration in CLL
Shares Sonrotoclax, Zanubrutinib, Chronic lymphocytic leukaemia.